Skip to main content
Sustainable Chemical Processes

Table 1 Current clinical trials of oligonucleotides modified with LNA [18]

From: An astute synthesis of locked nucleic acid monomers

S.no.

LNA modified oligonucleotide

Indication

Target

Clinical phase

1

Miravirsen (SPC-3649)

Hepatitis C virus (HCV)

MicroRNA-122

II

2

EZN-2968

Solid Tumours

Hypoxia-inducible factor-1 alpha (HIF-1α)

I

3

EZN-3042

Cancer

Survivin

I

4

EZN-4176

Cancer

Androgen receptor

I

5

SPC-4955

Hypercholesterolemia

Apolipoprotein B

I

Back to article page